4//SEC Filing
Pruzanski Mark 4
Accession 0001104659-23-117094
CIK 0001270073other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 2:40 PM ET
Size
33.6 KB
Accession
0001104659-23-117094
Insider Transaction Report
Form 4
Pruzanski Mark
DirectorPresident and CEO
Transactions
- Disposition from Tender
Common Stock
2023-11-08$19.00/sh−618,894$11,758,986→ 0 total - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−332→ 0 totalExercise: $266.01→ Common Stock (332 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−5,401→ 0 totalExercise: $266.01→ Common Stock (5,401 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−1,044→ 0 totalExercise: $161.16→ Common Stock (1,044 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−31,506→ 0 totalExercise: $161.16→ Common Stock (31,506 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−635→ 0 totalExercise: $94.29→ Common Stock (635 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−29,865→ 0 totalExercise: $94.29→ Common Stock (29,865 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−1,207→ 0 totalExercise: $107.18→ Common Stock (1,207 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−38,793→ 0 totalExercise: $107.18→ Common Stock (38,793 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−207→ 0 totalExercise: $58.74→ Common Stock (207 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−45,293→ 0 totalExercise: $58.74→ Common Stock (45,293 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−889→ 0 totalExercise: $110.80→ Common Stock (889 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−12,811→ 0 totalExercise: $110.80→ Common Stock (12,811 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-08−17,700→ 0 totalExercise: $99.66→ Common Stock (17,700 underlying)
Footnotes (2)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
- [F2]Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Documents
Issuer
INTERCEPT PHARMACEUTICALS, INC.
CIK 0001270073
Entity typeother
Related Parties
1- filerCIK 0001559569
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 2:40 PM ET
- Size
- 33.6 KB